Type I interferon induction of the cdk-inhibitor p21(WAF1) is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line

Oncogene

Volumn 16, Issue 14, 1998, Pages 1885-1890

  Subramaniam, Prem S ^a   Cruz, Pedro E ^a   Hobeika, Amy C ^a   Johnson, Howard M ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Apoptosis; B cell differentiation; Cell cycle; Interferon ; p21(WAF1)

Indexed keywords

GAMMA INTERFERON; INTERFERON; PROTEIN P21; RETINOBLASTOMA PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL DEATH; CELL DIFFERENTIATION; DAUDI CELL; DOWN REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL;

EID: 0032499223     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1201712     Document Type: Article

References (30)

1. Bertolni JN, Bertolni J, Thean E and Benson EM. (1992). J. Immunol., 149, 1771-1778.
2. Blagosklonny MV, Alvarez M, Fojo A and Neckers LM. (1996). Leukemia Res., 20, 101-107.
3. Burke LC, Bybee A and Thomas NS. (1992). Oncogene, 7, 783-788.
4. Clemens MJ, Tilleray VJ, James R, Gewert DR. (1988). J. Cell. Biochem., 38, 251-259.
5. Collins SJ. (1987). Blood, 70, 1233-1244.
6. Dimri GP, Nakanishi M, Desprez P-Y, Smith JR and Campisi J. (1996). Mol. Cell. Biol., 16, 2987-2997.
7. Einat M, Resnitzky D and Kimchi A. (1985). Nature, 313, 597-600.
8. Exley R, Gordon J, Nathan P, Walker L and Clemens MJ. (1987a). Int. J. Cancer., 40, 53-57.
9. Exley R, Gordon J and Clemens MJ. (1987b). Proc. Natl. Acad. Sci. USA, 84, 6467-6470.
10. Gartel AL, Serfas MS and Tyner AL. (1996). Proc. Soc. Exp. Biol. Med., 213, 138-149.
11. Hermeking H, Funk JO, Reichert M, Ellwart JW and Eick D. (1995). Oncogene, 11, 1409-1415.
12. Hobeika A, Subramaniam PS and Johnson HM. (1997). Oncogene, 14, 1165-1170.
13. Kumar R and Atlas I. (1992). Proc. Natl. Acad. Sci. USA, 89, 6599-6603.
14. Melamed D, Tiefenbrun N, Yarden A and Kimchi A. (1993). Mol. Cell. Biol., 13, 5255-5265.
15. Morgenbesser SD and DePinho RA. (1994). Semin. Cancer Biol., 5, 21-36.
16. Noguchi PD. (1992). Current Protocols in Immunology. Vol. 1., Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM and Strober W (eds). John Wiley & Sons, Inc: New York. p. 5.7.1.
17. Patel T, Gores GJ and Kaufmann SH. (1996). FASEB J., 10, 587-597.
18. Resnitzky D, Tiefenburn N, Berissi H and Kimchi A. (1992). Proc. Natl. Acad. Sci. USA, 89, 402-406.
19. Rubin BY, Sekar V and Martimucci WA. (1983). J. Gen. Virol., 64, 1743-1748.
20. Sangfeft O, Erickson S, Einhorn S and Grander G. (1997). Oncogene, 14, 415-423.
21. Steiner P, Philipp A, Lukas J, Godden-Kent D, Pagano M, Mittnacht J, Bartek J and Eilers M. (1995). EMBO J., 14, 4814-4826.
22. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA and El-Houseini ME. (1994). Oncogene, 9, 3389-3396.
23. Subramaniam PS and Johnson HM. (1997). J. Interferon Cytokine Res., 17, 11-15.
24. Tamm I, Jasny BR and Pfeffer LM. (1987). Mechanisms of Interferon Actions, Vol. II, LM Pfeffer (ed). CRC Press: Boca Raton, FL p. 25.
25. Thomas NS, Burke LC, Bybee A and Linch DC. (1991). Oncogene, 6, 317-322.
26. Tiefenbrun N, Melamed D, Levy N, Resnitzky D, Hoffman I, Reed SI and Kimchi A. (1996). Mol. Cell. Biol., 16, 3934-3944.
27. Tomita Y, Cantell K and Kutawa T. (1982). Int. J. Cancer, 30, 161-165.
28. Vlach J, Hennecke VJ, Alevizopolous S, Conti D and Amati B. (1996). EMBO J., 15, 6595-6604.
29. Yen A, Chandler S, Forbes ME, Fung YK, T'Ang A and Pearson R. (1992). Eur. J. Cell. Biol., 57, 210-221.
30. Zhang K and Kumar R. (1994). Biochem. Biophys. Res., Comm., 200, 522-528.